Vernon Bernardino, an analyst from H.C. Wainwright, has initiated a new Buy rating on MaaT Pharma (MAAT).
Vernon Bernardino has given his Buy rating due to a combination of factors that highlight the potential of MaaT Pharma’s lead product, MaaT013. The therapy is positioned to be the first approved third-line treatment for acute graft-versus-host disease (GvHD) with gastrointestinal involvement, an area currently lacking an FDA-approved solution. The positive Phase 3 trial results for MaaT013, demonstrating significant efficacy and safety, bolster confidence in its potential market adoption and de-risk future clinical trials in the U.S.
Furthermore, MaaT Pharma’s robust clinical-stage pipeline underscores its leadership in microbiome ecosystem therapies, which are designed to modulate the immune system. The anticipated submission of a Marketing Authorization Application to the EMA and the initiation of a U.S. Phase 3 trial are seen as key catalysts for the company’s growth. These factors collectively support Bernardino’s optimistic outlook and Buy rating for MaaT Pharma’s stock.
In another report released on April 2, Kepler Capital also maintained a Buy rating on the stock with a €15.50 price target.